# Gender Differences in Clinical Practice

Gender related differences in patient presentation, management and outcome across different manifestations of cardiovascular disease

Dr Caroline Daly, MB PhD Cardiologist, Dublin

### **Gender Differences: Historical Male Focus**

CORPUS CALLOSUM The bridge joining the two halves of the brain, called the corpus callosum, is larger in Marge than in Homer. Marge can integrate information from the two halves of the brain, meaning that she can simultaneously make Homer's lunch, listen to Lisa's saxophone playing and insure that Bart doesn't burn anything, while Homer has trouble combining singing and driving without crashing into a chestnut tree.

HEART AND CIRCULATORY SYSTEM While Marge is young, Bart's shenanigans are less likely to give her high-blood pressure than Homer's. Her higher levels of estrogen prevent cholesterol deposits from forming on artery walls. By the time Lisa graduates from Yale, however, Marge's risk for heart disease will begin to match his.


LYMPHATIC SYSTEM If Marge gets a cold, her immune system will respond more forcefully than Homer's immune system. But she is also more likely to suffer from diseases, like rheumatoid arthritis and lupus erythematosus, linked to a highly active immune system that malfunctions.

> LIVER Homer metabolizes beer faster and more efficiently than Marge does, so he is less likely to get a hangover. But that immunity may partly explain why more men are alcoholics.

No one can dispute that Homer is the gourmand of the Simpsons. He is unable to resist pork chops, chocolate and Vaseline. But in the unlikely event that he decided to lose weight, he could diet. For Marge, however, losing weight would require not only giving up Jello desserts, but exercising.

SKELETAL SYSTEM Homer's body will always produce testosterone, but estrogen production virtually halts when a women goes through menopause. Because these hormones rejuvenate bones, this means that while Homer will always survive cliff falls on Bart's skateboard

unscathed, Marge's bones could become more brittle.



## Sex differences in CV disease in 1990's

#### 1991 NEJM

#### Ayanian & Epstein

 Women presenting with coronary disease less likely to have invasive investigation, PTCA or surgery

#### SAVE Study

Less angiography in women post infarction

#### Wenger editorial

- "Yentl Syndrome"
- Reproach to "bikini" approach to womens' health, ignoring cardiovascular disease

## **Professional Society Support**

 2005 Women at Heart Initiative of ESC



 2005 Go Red For Women by AHA



# Scope of the problem

- Cardiovascular risks/1° and 2° prevention
  - Hypertension
  - Hyperlipidaemia
- Coronary Heart Disease
  - Angina
  - Acute coronary Syndrome/MI
- Heart Failure
- Arrhythmia
- Congenital Heart Disease

# Scope of the problem

- Epidemiology/Natural History
- Morbidity and mortality (incl temporal trends)
- Access to services
- Investigation
- Pharmacological treatment
- Other treatments eg revasculatisation

## **Euro Heart Survey Programme**

Programme of surveys launched 1999 by ESC

### Aims

- Applicability of evidence based medicine
- How clinical practice match guidelines
- Process and outcome associated with cardiac conditions in "real world", outside RCT's

## **Euro Heart Survey Programme**

	1996	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Prevention Euro Aspire	+	+							+		
Heart Failure			+				+				
Acute Coronary Syndromes (ACS)		+				+					+
Valvular HD				+							
Revascularisation			+					+			
Angina					+						
Diabetes					+						
Atrial Fibrillation						+					
Adult Congenital Heart Disease						+					

# Scope of the problem

Cardiovascular risks/Primary prevention

- Hypertension
- Hyperlipidaemia
- Coronary Heart Disease
  - Angina
  - Acute coronary Syndrome/MI
- Heart Failure
- Arrhythmia
- Congenital Heart Disease

Age-Adjusted and Age-Specific Hypertension Awareness, Treatment, and Control in the U.S. Population Aged 60 and Older with Hypertension: National Health and Nutrition Examination Survey (NHANES) III (1988–1994) and NHANES 1999–2004

		NHANES II	Ι	NHANES 1999–2004				
			Control in			Control in		
	Aware	Treated	Treated	Aware	Treated	Treated		
	Percent							
Total	70	58	36	74	67	43		
Sex								
Male	65	52	39	74	68	51		
Female	74	62	35	74	67	37		

## EUROASPIRE I, II & III 1995/6, 1999/2000 & 2006/7

	Raised blood pressure		Raised cholesterol			<b>Reported diabetes</b>			
	I	II	Ш	I	II	Ш	I	II	Ш
Man	1345/2388	1270/2223	1106/1835	1686/1794	1554/2078	756/1747	388/2389	411/2222	476/1822
Men	(56·3%)	(57·1%)	(60·3%)	(94.0%)	(74.8%)	(43·3%)	(16·2%)	(18·5%)	(26·1%)
	502/790	460/746	346/550	582/605	568/688	293/526	164/791	187/748	188/549
Women	(63·5%)	(61.7%)	(62·9%)	(96·2%)	(82.6%)	(55.7%)	(20.7%)	(25.0%)	(34·2%)

Mean age 59, 25% female

Kotseva Lancet 2009

### **EUROASPIRE I, II & III** Proportion of pts achieving target BP

No blood pressure lowering Tx Blood Pressure Lowering Tx

	I	Ш	III	I	П	Ш
Men	182/393	104/219	32/62	861/1995	849/2004	693/1761
	(46·3%)	(47·5%)	(51.6%)	(43·2%)	(42·4%)	(39·4%)
Women	47/99	28/60	8/12	241/691	258/686	196/535
	(47·5%)	(46·7%)	(66·7%)	(34·9%)	(37·6%)	(36·6%)

Mean age 59, 25% female

Kotseva Lancet 2009

# Scope of the problem

- Cardiovascular risks/Primary prevention
  - Hypertension
  - Hyperlipidaemia
- Coronary Heart Disease
  - Acute coronary Syndrome/MI
  - Angina
- Heart Failure
- Arrhythmia
- Congenital Heart Disease

## **Meta-analysis of RCT data on ACS**

Table 1. Summary of Trials Used in the Study


	No./Total No. (%)	of Patients Enrolled				
Source	Women	Men	Type of ACS Evaluated	Intervention		
GUSTO I, <sup>25</sup> 1993	10315/40968 (25.2)	30 653/40 968 (74.8)	STEMI	Streptokinase and subcutaneous heparin, streptokinase and intravenous heparin, accelerated tissue plasminogen activator and intravenous heparin, or a combination of streptokinase plus tissue plasminogen activator with intravenous heparin		
GUSTO IIb, <sup>26</sup> 1996	3661/12 140 (30.2)	8479/12 140 (69.8)	STEMI, NSTEMI, unstable angina	Heparin; hirudin		
GUSTO III, <sup>27</sup> 1997	4124/15059 (27.4)	10935/15059 (72.6)	STEMI	Tissue plasminogen activator; reteplase		
ASSENT II, <sup>28</sup> 1999	3930/17 004 (23.1)	13074/17004 (76.9)	STEMI	Tissue plasminogen activator; tenecteplase		
ASSENT III, <sup>29</sup> 2001	1438/6116 (23.5)	4678/6116 (76.5)	STEMI	Full-dose tenecteplase and heparin; full-dose tenecteplase and enoxaparin; half-dose tenecteplase and abciximab		
ASSENT III+, <sup>30</sup> 2003	378/1639 (23.1)	1261/1639 (76.9)	STEMI	Full-dose tenecteplase and heparin; full-dose tenecteplase and enoxaparin		
HERO 2, <sup>31</sup> 2001	4850/17 087 (28.4)	12 237/17 087 (71.6)	STEMI	Bivalirudin; heparin; streptokinase		
PURSUIT, <sup>32</sup> 2000	3857/10947 (35.2)	7090/10947 (64.8)	NSTEMI, unstable angina	Placebo; low-dose eptifibatide; high-dose eptifibatide		
PARAGON A, <sup>33</sup> 1998	776/2262 (34.3)	1486/2262 (65.7)	NSTEMI, unstable angina	Low-dose lamifiban with and without heparin; high-dose lamifiban with and without heparin		
PARAGON B, <sup>34</sup> 2000	1789/5225 (34.2)	3436/5225 (65.8)	NSTEMI, unstable angina	Lamifiban; heparin		
GUSTO IV, <sup>35</sup> 2001	2930/7800 (37.6)	4870/7800 (62.4)	NSTEMI, unstable angina	Heparin; 24-h abciximab; 48-h abciximab		
Total	38048/136247 (27.9)	98199/136247 (72.1)				

Abbreviations: ACS, acute coronary syndromes; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

#### Berger, J. S. et al. JAMA 2009;302:874-882.



Unadjusted and Multivariable-Adjusted 30-Day Mortality Models in Women vs Men Across the Spectrum of ACS (n = 136 247)



Berger, J. S. et al. JAMA 2009;302:874-882.


JAMA

### **Euro Heart Survey of Acute Coronary Syndromes I**

- Pan European Survey of patients with acute coronary syndromes presenting to hospitals across Europe
- Diagnosis of ACS at presentation assessed
- Use of investigations and treatments surveyed
- In hospital outcome assessed in this analysis

Enrollment: September 2000 to May 2001

### EHS ACS I Initial Diagnosis



n=10,253

ST elevation MI

Non ST elevation ACS

Undetermined

### **Gender differences at presentation**

Women are older, more likely to have a history of diabetes or hypertension and less likely to smoke


#### Women less than 65

- More atypical chest pain OR 1.7 (1.3-2.2)
- More normal ECG's OR 1.3 (1.1-1.5)
- Higher HR and Systolic
  BP

#### Women over 65

- Symptoms and ECG findings similar
- Higher HR and Systolic BP
- Greater severity of Killip Class. p=0.009

## "Normal" coronary angiography




ACS pts undergoing angio


### Variation in Spectrum of ACS

- Discharge diagnosis of "Unstable Angina" more likely in younger women OR 1.56 (1.35-1.79), not so in older age group
- Hochman et al, NEJM 1999 (GUSTO IIb)
- Pifferent pathophysiological process at play
- Finding confirmed in unselected population and found to be significantly age dependent


### Reperfusion therapy (ST elevation MI only)



## **In-Hospital mortality**




## **In-Hospital mortality**



#### EHS PCI survey (2005):

#### Predictors of in-hospital MACCE in STEMI patients Baseline data and angiographic information (n=2621)



### Summary of gender differences in ACS I


- Women are more likely to present with non ST elevation MI or have unstable angina than men
- Women have more adverse baseline characteristics and older women present with more worse clinical predictors (Killip Class etc)
- Women with ST elevation are 1/3 less likely than men to receive reperfusion
- Crude in-hospital mortality for women is twice that of men, but after adjustment differences not significant

### Gender related coronary disease manifestations


First manifestations of CHD by sex from 26 year follow-up of Framingham (Lerner & Kannel 1986) Reunanen et al '85 Men

MI	43%	
followed by Angina	26%	<b>29%</b>
then sudden death	10%	
In Women the distribution of events	is changed	
MI	29%	
Angina	47%	50%
sudden death	7 %	

### Age and sex specific incidence of Angina



### Age and sex specific incidence of Angina




### **Prevalence of Stable Angina**

Study	Country	Years	Age	Definition	Male	Female
	Wales	1967	30-74	Rose		17.8%
9 Comm	Italy	1978-79	30-69	Rose	2.3%	3.1%
SHS	Scotland	1979-80	40-59	Rose	6.3%	8.5%
BRHS	UK	1978-80	40-59	Rose	4.8%	
EPES	USA	1981-83	>65	Rose	3-4%	4-6%
CVHS	USA	1989-90	>65	Confirmed self-report	16%	10%
NHANES	USA	1988-94	40-65	Rose	5.2%	6.2%
PANES	Spain	1990's	30-69	Rose	7.3%	7.8%



Israel/ Librach Denmark/ Hagerup (40) England/Harland (Chinese) England/ Patel Hong Kong/ Woo USA/ Ford (Black 1971) India/ Nazareth India/ Singh (Rural) Denmark/ Hagerup (50) Ireland/ Shelley England/ Fischbacher (South Asian India/ Singh (Urban) England/ Dewhurst Denmark/ Agner Sweden/ Glader (1994) Ghana/ Watkins Japan/ Sekine Sweden/ Cederholm USA/ Smith (White) Taiwan/ Chen USA/ Mittlemark England/ Harland (Europid) Sweden/ Glader (1986) USA/ Ford (Black 1976) Scotland/ Kitchin Spain/ Masia USA/ Smith (Black) Hong Kong/ Lam USA/ Lacroix (Black) Canada/ Reeder Finland/ Ahto Turkey/ Onat USA/Lacroix (Hispanic) Jamaica/ Miall Sweden/ Lernfelt USA/ Ford (Hispanic) USA/ Ford (Black) Lithuania/ Bluzhas Italy/ Cacciatore West Germany/ Todzy USA/ Wilcosky Finland/ Lahelma Italy/ Krogh USA/ Ford (White 1971) USA/ Sorlie (Black) Switzerland/ Gutzwiller USA/ Langford (White) Iran/ Sarraf-Zadegan USA/ Langford (Black) Scotland/ Smith Taiwan/ Lin Georgia/ Balabadze South Africa/ Rossouw India/ Gopinath England/ Nicholson Sri Lanka/ Mohideen USA/ Ford (White) USA/ Lacroix USA/ Ford (White 1976) USA/ Lacroix (White) Finland/ Reunanen Netherlands/ Grobee Russian Federation/ Bobak Czech Republic/ Bobak USA/ Sorlie (White) Scotland/ Smith Spain/ Cosin Denmark/ Jensen Poland/ Bobak Scotland/ Hart West Germany/ Helmert United Kingdom/ Feinleib Belgium/ De Bacquer Norway/ Feinleib Overall (I-squared = 74.2%, p = 0.000)




Sex ratios in **Rose angina** prevalence ([PR] 95% Cls)


Hemingway, H. et al. Circulation 2008;117:1526-1536




## **Liverpool Primary Care Study 2001**




## **Liverpool Primary Care Study 2001**




Temporal Changes in Rates of Cardiac Stress tests without imaging per 1000, by Gender, Adjusted for Age, Medicare, 1993–2001



#### Temporal Changes in Rates of Cardiac Stress Imaging Procedures per 1000, by Gender, Adjusted for Age, Medicare, 1993–2001




#### Temporal Changes in Rates of Cardiac Catheterisation Procedures per 1000, by Gender, Adjusted for Age, Medicare, 1993–2001



## **Standardised Mortality Rates in Angina**

### Hemingway JAMA 2007



### **Gender Differences in Angina**

### **Euro Heart Survey of Stable Angina**

Daly et al Circulation 2006

### **Euro Heart Survey of Angina**

- Pan European Survey of patients with **stable angina** presenting to cardiologists in Europe, with one year follow-up
- Based on ambulatory, non hospitalised patients
- Full complement of investigations and treatments surveyed across countries, also clinical outcome

Initial survey:March 2002 to December 2002Follow up:March 2003 to January 2004

### Which patients?

### **EHS** Angina

#### Definition

- Out-patient at a <u>new presentation</u> to a <u>cardiologist</u>
- in whom <u>diagnosis is made</u>, on clinical assessment,
- of <u>stable angina</u> caused by myocardial ischaemia
- due to coronary disease,
- and who does not have unstable angina.

Excluding patients with Class IV symptoms, those admitted to hospital within 24 hrs, those with prior revascularisation, or MI within 1 year


	Male n=2196	Female n=1582	ρ	Overall
Mean age (± sd)	60 (11)	62 (11)	< 0.0001	61 (11)
Diabetic	17%	19%	0.17	18%
Hypertensive	58%	66%	< 0.0001	62%
Hyperlipidaemia	57%	59%	0.24	59%
Ever Smoked	69%	30%	<0.0001	57%
Periph. Vasc. Dis	7%	7%	0.32	7%
Prior CVA/TIA	6%	4%	0.02	5%
Prior MI (>1 year)	5%	3%	0.004	4%
CCS Class I	39%	32%		36%
CCS Class II	43%	47%	<0.0001	45%
CCS Class III	12%	11%		12%
Signs of HF	8%	8%	0.81	8%

#### Completeness of follow up

#### **EHS** Angina


- Initial survey n=3779
- Total Follow up94%
- Suitable for analysis n=3031
- Final Follow up80%

#### Effect of sex on use of investigations: Initial 4wks



Less likely to have test More likely to have test


# Medication post initial assessment for patients withcompleted follow upEHS Angina



#### Investigations performed in 1 yr EHS Angina


	Male	Female	p value	Overall
Echo	64%	65%	0.37	64%
Ex ECG	78%	73%	0.001	76%
Stress Echo	4%	4%	0.14	4%
Perfusion	13%	15%	0.35	14%
Angiography	47%	34%	<0.001	41%

#### **Coronary Disease Status at 1 year EHS Angina**



#### **Results of angiography EHS Angina**





#### Meds at 1 year in those with confirmed CAD

	Male	Female	p value	Overall
Antiplatelet	94%	92%	0.156	93%
Lipid Iowering	82%	76%	0.057	80%
Antiplatelet & lipid low.	78%	71%	0.013	76%
<b>B</b> Blocker	77%	82%	0.141	78%

#### Effect of sex on revascularisation EHS Angina

	*Adj. OR F vs M	p value
Revascularisation planned/performed within 4 wks	0.56	<0.001
Revascularisation at 1 year	0.19	<0.001
Revascularisation at 1 year in women with CAD	0.68	0.002

\*Adjusted for age, symptom severity and other factors predictive at univariate level

#### Effect of sex on risk of death/MI EHS Angina

	*MV HR	95% CI	p value
Female vs Male	2.08	1.13-3.83	0.01
Abnormal LV Fxn.	2.03	1.04-3.94	0.04

Multivariate HR adjusted for age, DM, LV function and severity of CAD

#### Summary I

#### **EHS** Angina

- Significantly less use of antiplatelet and lipid lowering therapy in women even after CAD has been confirmed
- Women with angina are significantly less likely to receive either non-invasive or invasive investigation, even after adjustment for age, comorbidity, symptom severity or the results of preliminary investigation.

### **Summary II**

### **EHS** Angina

- Women significantly less likely to receive revascularisation than men, even in the presence of confirmed CAD
- Women with angina and confirmed CAD have a significantly worse prognosis than men
- more than twice as likely to suffer death or MI during follow up, independent of the effects of age, diabetes, LV function or severity of CAD

### **Conclusions of EHS Angina**

Women with stable angina are

- Under-investigated
- Under-treated


even though

- Symptoms more severe
- Women with proven CAD have worse prognosis

## Scope of the problem

- Cardiovascular risks/Primary prevention
  - Hypertension
  - Hyperlipidaemia
- Coronary Heart Disease
  - Angina
  - Acute coronary Syndrome/MI
- Heart Failure
- Arrhythmia
- Congenital Heart Disease

### **Population prevalence**



\*based on clinical criteria \*\*based on echocardiography

#### Gender differences in care of Heart Failure-UK data, primary care


Median age (yr)	F/M
73	60/40
e 76	47/53
ital 71	48/52
80	70/30
	73 e 76 ital 71

Clarke et al, Br Heart J 1994

### **Euro Heart Survey of Heart Failure I**

- N= 11304 patients from across Europe
- 116 hospitals
- Suspected or confirmed Heart Failure
- Mean age 71years, 53% male
- First diagnosis on index admission in 27%

# EF in women (2048; 41% of total enrolled) and men (3249; 57% of total enrolled) in EHS Heart Failure I



Left Ventricular Ejection Fraction (%)

51% of men but only 28% of women had a left ventricular EF <40%

### OR (adj) of use of medication for men v women in EHS Heart Failure I

Odds ratio (95% CI)

B Blockers CCB Anti thrombotic ACE i Spironolactone Aspirin

- 1.16 (1.05 to 1.29)\*
- 0.79 (0.71 to 0.88)\*
- 1.19 (1.00 to 1.40)
- 1.34 (1.22 to 1.48)\*
- 1.28 (1.15 to 1.43)\*
- 1.34 (1.23 to 1.46)\*

#### Montreal multidisciplinary HF clinics 2000-02

#### N= 765, 27% female, mean age 65 yrs

Hospital admissions with CHF: 3006 men 2890 women

	All, %	Men, %	Women, %	Р
Beta-blockers	78	81	71	0.003
ACE inhibitors	74	77	66	0.001
ARBs	21	20	25	0.138
ACE or ARBs	88	90	82	0.002
Nitrates	50	51	46	0.173
Cardiac glycoside	69	69	67	0.477
Antiplatelet agents	56	57	51	0.129
Diuretics	89	91	86	0.040
Antiarrhythmic	24	27	17	0.006

### Montreal Study: use of meds


Use of medications	OR	CI
BB	0.58	0.32-0.78
ACE or ARB	0.50	0.32-0.78
	Adjusted OR	CI
BB (adjusted for Systolic Function)	0.77	0.50-1.19
ACE or ARB (adjusted for Systolic Function)	0.80	0.44-1.44

Use According to Canadian Guidelines	Men	Women	р
BB	87%	82%	0.21
ACE	84%	75%	0.06
ACE or ARB	97%	95%	ns

### **Euro Heart Survey Heart Failure II**

- 133 hospitals in 30 European countries
- October 2004 to August 2005
- Patients admitted to hospital with dyspnoea and verification of HF (new-onset AHF or ADCHF) based on (i) symptoms and signs of HF and (ii) lung congestion on chest X-ray.
- n=3580 patients

### **Euro Heart Survey Heart Failure II**



### Gender differences EHS Heart Failure II

- Diuretics
- Aldosterone antagonists
- ACE inhibitors (ACEI)
- Angiotensin receptor blockers (ARB)
  Angiotensin receptor blockers (ARB)
- Beta-blockers
- Digitalis compounds
- Anti-arrhythmic drugs
- Calcium channel blockers
- Oral nitrates
- Aspirin
- Vitamin K antagonist
- Lipid regulating drugs
- Insulin
- Oral antidiabetics

- Echocardiography
- Exercise testing
- Holter monitoring
- B) Arterial line
  - Pulmonary artery catheter
  - IABP
  - Thrombolysis
  - Coronary angiography
  - PCI/CABG
  - Heart transplantation
  - BNP/NT-proBNP tested
  - Length of stay (days)
  - Admission to ICU/CCU
  - In hospital Mortality
  - Death, MI or stroke

### **NO** Gender differences EHS Heart Failure II


- **Diuretics**
- Aldosterone antagonists
- ACE inhibitors (ACEI)
- tifferences Angiotensin receptor
- **Beta-blockers**
- Digitalis compo
- Anti-arrhythr Jgs
- significant di blockers Calcium ch
- Oral nit
- Aspir
- Vi<sup>+</sup> K antagonist
- Lip egulating drugs
- Insulin
- **Oral antidiabetics**

- Echocardiography
- **Exercise testing**
- Holter monitoring
- ers (ARB) = **Arterial line**
- ifferences Pulmonary art
  - **IABP**
  - Thrombo
  - ·cant Gography Coronz

neter


- PCI/
  - Н ansplantation
  - NT-proBNP tested
- NO ngth of stay (days)
- Admission to ICU/CCU
- In hospital Mortality
- Death, MI or stroke

#### Expected survival curves for 60 and 80 year old men and women hospitalised for acute heart failure




Nieminen, M. S. et al. Eur J Heart Fail 2008 10:140-148;

#### Adjusted risk of death at 5 years in men and women (diabetics v non diabetics). Excluding patients who died in the first 30 days.



Patients discharged from hospital in Scotland (n=116 556) from 1986 to 2003 with a diagnosis of HF analysed by diabetes and sex

#### NHANES I, II and III: Diabetes And CVD mortality



Cohort Follow-up Period

### Conclusions

- Systematic bias in the use of investigations and treatment across range of indications
- Lack of improvement in age standardised CVD mortality rates for women
- Early signs that awareness and vigilance can improve discrepancies, await impact on morbidity and mortality